PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01829893 |
Recruitment Status :
Completed
First Posted : April 11, 2013
Last Update Posted : April 11, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Benign Prostatic Hyperplasia (BPH) | Drug: In combination of 0.2mg finasteride and 5mg tamsulosin Drug: GL2701 capsule | Phase 1 |
This single dose, open label, balanced, randomized, two-treatment, two-period, two-sequence, crossover study was conducted to compare the relative bioavailability and pharmacokinetic characteristics of a newly developed formulation with a conventional formulation in healthy subjects.
For this, a single-center, randomized, single-dose, open-label, 2-period and 2-sequence crossover study with a 14-day washout period was conducted in 26 healthy volunteers. Plasma samples for the analysis of finasteride/tamsulosin were collected up to 48 h after drug administration. Participants received either reference (in combination of of 0.2mg tamsulosin and 5mg finasteride) or test drug formulation (single pill combination of 0.2mg tamsulosin and 5mg finasteride) in the first period and the alternative formulation in the second period. Plasma concentrations of both tamsulosin and finasteride were determined by validated high-performance liquid chromatography coupled to tandem mass spectrometry detection. Pharmacokinetic parameters, including Cmax and AUC, were determined by noncompartmental analysis. Analysis of variance (ANOVA) was carried out using log-transformed Cmax and AUC, and the mean ratios and their 90% confidence intervals (CI) were calculated. According to regulatory requirements set forth by Korea and the US Food and Drug Administration, products meet the criteria for bioequivalence if the 90% CIs of the mean ratios for Cmax and AUC are within the range of 0.80 to 1.25.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 26 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Official Title: | Open Label, Randomized Comparative Study to Evaluate the Pharmacokinetic Characteristics Between Coadministered Finasteride Tablet and Tamsulosin HCl Tablet and GL2701 Capsule, in Healthy Subjects |
Study Start Date : | January 2012 |
Actual Primary Completion Date : | February 2012 |
Actual Study Completion Date : | February 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Reference arm
Treated with Reference (in combination of 0.2mg tamsulosin and 5mg finasteride) Intervetion: In combination of 0.2mg finasteride and 5mg tamsulosin simultaneously
|
Drug: In combination of 0.2mg finasteride and 5mg tamsulosin
oral medication with 240 mL water
Other Name: GL2701 capsule |
Experimental: Test arm
Treated with Test formulation (single pill combination of 0.2mg finasteride and 5mg tamsulosin) Intervention : GL2701 capsule
|
Drug: GL2701 capsule
oral medication with 240 mL water
Other Names:
|
- Finasteride and Tamsulosin pharmacokinetics (Cmax and AUC) [ Time Frame: 48 hr ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Males age 20 to 45 years
- Body weight > 50 kg with 18~29 kg/m2 body mass index (BMI)
- Signed and dated informed consent form which meets all criteria of current FDA and KFDA regulations
Exclusion Criteria:
- subjects with acute conditions.
- presence of history affecting ADME
- Clinically significant history or current evidence of a hepatic, renal, gastrointestinal, or hematologic abnormality
- Hepatitis B, hepatitis C, or HIV infection revealed on the laboratory findings
- Any other acute or chronic disease
- A history of hypersensitivity to donepezil
- A history of alcohol or drug abuse
- Participation in another clinical trial within 3 months
- smoked >10 cigarettes daily
- consumption over 5 glasses daily of beverages containing xanthine derivatives
- use of any medication having the potential to affect the study results within 10 days before the start of the study.
- AST or ALT > 1.25 of upper normal limit
- total bilirubin > 1.5 of upper normal limit
- systolic blood pressure < 90 mmHg
- calculated CLcr using Cockroft-Gault equation < 50 mL/min

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01829893
Korea, Republic of | |
Clinical trial center of Anam Hospital | |
Seoul, Korea, Republic of, 136-705 |
Principal Investigator: | Ji-Young Park, MD, PhD | Department of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine |
Responsible Party: | Ji-Young Park, Associate Professor, Korea University Anam Hospital |
ClinicalTrials.gov Identifier: | NCT01829893 |
Other Study ID Numbers: |
GP-FITAM-104 |
First Posted: | April 11, 2013 Key Record Dates |
Last Update Posted: | April 11, 2013 |
Last Verified: | December 2011 |
Benign Prostatic Hyperplasia (BPH) pharmacokinetics bioequivalence finasteirde tamsulosin |
Prostatic Hyperplasia Hyperplasia Pathologic Processes Prostatic Diseases Tamsulosin Finasteride Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents 5-alpha Reductase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists |